Vaccination against transplacental cytomegalovirus transmission: vaccine reactivation and efficacy in guinea pigs.
The guinea-pig model of cytomegalovirus (CMV) infection was used in continuing studies of experimental CMV vaccines for prevention of congenital CMV infection. Low-passage guinea-pig cytomegalovirus (GPCMV) vaccine, which has been shown to be effective in preventing transplacental CMV transmission, was tested for reactivation during pregnancy. In Hartley strain guinea pigs intraperitoneally given 10(5.5) 50% tissue culture infective doses (TCID50) of low-passage vaccine, 27 (41%) of 66 throat swabs obtained during subsequent pregnancies showed CMV, in contrast to 28 (24%) of 115 throat swabs obtained from nonpregnant control animals. High-passage GPCMV vaccine (approximately 5 X 10(3) TCID50) did not cause acute viremia, detectable generalized infection, or GPCMV reactivation during subsequent pregnancies. Immune pregnant animals and their fetuses were protected against generalized CMV infection when challenged with virulent GPCMV. In contrast, nonimmune pregnant controls developed generalized maternal, placental, and fetal infection. Experimental low-dose, high-passage GPCMV vaccine can protect against transplacental CMV transmission without apparent vaccine reactivation during pregnancy.
D000818:Animals; D000914:Antibodies, Viral / Q000096:biosynthesis; D003587:Cytomegalovirus / Q000254:growth & development / Q000276:immunology*; D003586:Cytomegalovirus Infections / Q000517:prevention & control / Q000635:transmission*; D005260:Female; D005315:Fetal Diseases / Q000517:prevention & control*; D006168:Guinea Pigs; D006968:Hypersensitivity, Delayed; D008431:Maternal-Fetal Exchange; D010920:Placenta / Q000382:microbiology*; D011247:Pregnancy; D011251:Pregnancy Complications, Infectious / Q000517:prevention & control*; D014611:Vaccination; D014765:Viral Vaccines; D014766:Viremia; D014775:Virus Activation
D000914:Antibodies, Viral; D014765:Viral Vaccines